

Ergotrate Maleate advertisement.

[s.l.]: [s.n.], 1964


<https://digital.library.wisc.edu/1711.dl/MLGFGWUPXS5GE85>

<http://rightsstatements.org/vocab/InC/1.0/>

The libraries provide public access to a wide range of material, including online exhibits, digitized collections, archival finding aids, our catalog, online articles, and a growing range of materials in many media.

When possible, we provide rights information in catalog records, finding aids, and other metadata that accompanies collections or items. However, it is always the user's obligation to evaluate copyright and rights issues in light of their own use.

A better way to administer an oxytocic



Ready-to-use prefilled syringe

Saves time — no assembly or disassembly

Assures accurate dosage — prefilled, premeasured dose


Prevents cross-contamination — individual syringe and new extra-sharp needle

Ergotrate® Maleate is recommended for the prevention or treatment of postpartum or postabortal hemorrhage due to uterine atony. Given in the puerperium, Ergotrate Maleate may be helpful in preventing puerperal morbidity. Each Hyporet® (disposable syringe, Lilly), ampoule, or tablet contains 1/320 grain (0.2 mg.) of ergonovine maleate. Each

Hyporet or ampoule also contains ethyl lactate, 0.1 percent, lactic acid, 0.1 percent, and phenol, 0.25 percent, as a preservative.

Side-Effects: In a small percentage of patients, blood pressure may rise temporarily to abnormal levels. Allergic reaction is rare. No specific contraindications to Ergotrate Maleate have been reported.

New Hyporet®
ERGOTRATE® MALEATE
ERGONOVINE MALEATE



401380

Additional information available to physicians upon request. Eli Lilly and Company, Indianapolis 6, Indiana.